HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2014
- Study 202 interim results presented, evaluating investigational new drug PEGPH20
with gemcitabine and ABRAXANE® (nab-paclitaxel) in Stage IV pancreatic cancer patients -
- Continued growth in royalty revenues -
- Global collaboration with Janssen to develop and commercialize
subcutaneous products using ENHANZETM technology -
SAN DIEGO, March 2, 2015 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2014. Financial highlights for the fourth quarter include revenues of $30.4 million and a net loss of $5.3 million, or $0.04 per share. This compares to revenues of $12.5 million and a net loss of $22.0 million, or $0.19 per share, for the fourth quarter of 2013. Financial highlights for the full year 2014 include revenues of $75.3 million and a net loss of $68.4 million, or $0.56 per share. This compares to revenues of $54.8 million and a net loss of $83.5 million, or $0.74 per share, in the prior year.
“This has been a remarkable year of growth and progress for Halozyme. We achieved record revenues for the quarter and year, received the first U.S. approval and launch of a Biologics License Application utilizing our ENHANZE™ technology with the approval of Baxter’s HYQVIA, and announced the launch of our third partnered product, MabThera® SC in Europe,” said Dr. Helen Torley, President and Chief Executive Officer. “With continued projected growth in our royalty revenues, multiple near-term milestones for our investigational new drug PEGPH20, and a strong financial position, we believe we are well-positioned to grow shareholder value in 2015 and beyond.”
The following information was filed by Halozyme Therapeutics Inc (HALO) on Monday, March 2, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Halozyme Therapeutics Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed, and by Halozyme Therapeutics Inc.
Ticker: HALO CIK: 1159036 Form Type: 10-K Annual Report Accession Number: 0001159036-15-000041 Submitted to the SEC: Mon Mar 02 2015 4:17:23 PM EST Accepted by the SEC: Mon Mar 02 2015 Period: Wednesday, December 31, 2014 Industry: Biological Products No Disgnostic Substances